Catalyst Brief

← Calendar

Readoutin 45d

Merck Sharp & Dohme LLC — Pembrolizumab

Phase 3 primary completion: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992).

Date
Jan 2027
Type
Readout
Indication
Urinary Bladder Neoplasms

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Merck Sharp & Dohme LLC

  1. Jan2027
  2. Nov2026